Clinical Trial Search

Primary: Percentage of Patients With Adverse Events — 169; 174; 86; 90 Participants

Primary: Bronchodilation — 1.18; 2.72; 1.22; 2.90 liters — p=>0.05

Primary: Average Nasal Symptom Score Over Days 1-4 (ANSS1-4) — 3.428; 3.336 Score on a scale — p=0.516

Primary: Percentage of Patients With a Drug-related Adverse Event That is Recorded as Grade 3 or 4 or as a Serious Adverse Event (SAE) — 53.1; 53.1; 29.1; 27.3 percentage of…

Primary: Post-Operative Opioid Requirement — 11.0; 10.1 Morphine Equivalents

Primary: Percentage of Participants Achieving an SLE Responder Index Response at Week 52 — 38.5; 34.8; 27.7 percentage of participants

Primary: Objective Response Rate at 6 Months — 7.7; 9.2; 1.6 % participants

Primary: ≥20% Reduction in Lesion Size at 48 to 72 Hours Compared to Baseline in All Randomized Patients. — 80.9; 81.0 percentage of participants

Primary: Blood Pressure (BP) Change — 145.77; 145.67; 140.55; 142.62 mm Hg

Primary: Change in Montgomery-Åsberg Depression Rating Scale — 9.4; 6.4 units on a scale — p=0.89

Primary: Number of Participants With Adverse Events — 398; 302; 34; 0 Participants

Primary: Change From Baseline at Week 40 in Serum Phosphorus — 0.96 mg/dL — p=< 0.0001

Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post Treatment (SVR12) — 81.3 percentage of participants

Primary: Percentage Change in Park-based Physical Activity — 11.2; 6.1; 5.6; 8.4 Percent change in MET-hours — p=.0063

Primary: Number of Patients With Improvement in Hyperhidrosis Severity at Week 1 or Week 4 as Measured by the Hyperhidrosis Disease Severity Scale (HDSS). — 4 participants